Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
68562-41-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
Recombinant human insulin-like growth factor 1 (IGF-1)growth factor replacement biologic
Mechanism of action
Binds and activates the IGF-1 receptor, stimulating cellular growth, differentiation and metabolism. It provides replacement of deficient IGF-1 activity in severe primary IGF-1 deficiency.
Indications / reported uses
Treatment of growth failure in paediatric patients aged 2 years and older with severe primary IGF-1 deficiency or growth hormone gene deletion with neutralising antibodies to growth hormone; not a substitute for growth hormone in other causes of short stature
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Mecasermin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mecasermin Permitted Daily Exposure (PDE) report (the Mecasermin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mecasermin Occupational Exposure Limit (OEL) report (the Mecasermin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.